Clinical trials: in Burkina Faso
Malaria,Falciparum
A Study to Assess the Experimental Malaria Vaccines R78C and RH5.1 Combined With R21/Matrix-M (a "Multi-stage" Malaria Vaccine)
This is a Phase Ib age de-escalation, dose escalation, open-label study to assess the safety and immunogenicity of the multi-stage malaria vaccine candidate R21 plus RH5.1 and/or R78C in Matrix-M in adults aged 18-35 years and…
- Trial name
- VAC093 (NCT06958198)
- Testing
- R21, RH5.1, R78C
- Where
- Burkina Faso
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- University of Oxford
Malaria,Falciparum
A Study to Assess the Experimental Malaria Vaccines R78C and RH5.1 With Matrix-M in Combination With R21/Matrix-M
This is a Phase IIb randomised controlled trial of the safety, immunogenicity and efficacy of the malaria vaccine candidates R78C with Matrix-M™, and the combination of RH5.1 and R21 with Matrix-M™, in children aged 5-36 months…
- Trial name
- VAC087 (NCT07183371)
- Testing
- R21, RH5.1, R78C
- Where
- Burkina Faso
- Volunteers
- 360 people, healthy volunteers welcome
- Sponsor
- University of Oxford
Malaria,Falciparum
A Study to Test Experimental Blood Stage Malaria Vaccine in Burkina Faso.
This is a Phase IIb randomised controlled trial of the safety, immunogenicity and efficacy of the blood-stage malaria vaccine candidates RH5.1 in Matrix-MTM and RH5.2-VLP in Matrix-MTM in infants aged 5-17 months in Burkina Faso
- Trial name
- NCT05790889
- Testing
- Rabies vaccine, RH5.1 10μg adjuvated with 50μg Matrix-M, RH5.2 5μg adjuvated with 50μg Matrix-M
- Where
- Burkina Faso
- Volunteers
- 390 people, healthy volunteers welcome
- Sponsor
- University of Oxford
COVID-19
Variants of SARS-CoV-2 Causing COVID-19 in Africa
The main objective of this research is to identify and characterize the different molecular variants of SARS-CoV-2, emerging and / or circulating in several countries of Sub-Saharan Africa (Burkina Faso, Côte d'Ivoire, Gabon…
- Trial name
- South-Spike (NCT05311891)
- Testing
- RT PCR
- Where
- 6 sites in Burkina Faso, Chad and 4 more
- Volunteers
- 12,600 people, healthy volunteers welcome
- Sponsor
- ANRS, Emerging Infectious Diseases
Older Adults
Frailty, Geriatric Syndromes and Care Pathways of Older Adults Living With HIV in West Africa
With currently available antiretroviral therapy, people living with HIV (PLWHIV) are living longer. This exposure to HIV and combination antiretroviral therapy may accelerate the aging of this population, thus increasing the…
- Trial name
- NCT07355413
- Where
- 6 sites in Burkina Faso, Côte d’Ivoire and 1 more
- Volunteers
- 600 people, healthy volunteers welcome
- Sponsor
- ANRS, Emerging Infectious Diseases
Malaria Vaccines, Malaria (Plasmodium Falciparum)
Infant Malaria Vaccine Schedule Optimization
The aim of this study is to identify an optimal infant vaccine schedule for a malaria vaccine which is better aligned with the timing of other vaccine interventions.
- Trial name
- NCT06879327
- Testing
- R21 Matrix-M (R21/MM) Malaria Vaccine, Hexavalent Vaccine, Pneumococcal Polysaccharide Conjugate Vaccine
- Where
- 2 sites in Burkina Faso
- Volunteers
- 975 people, healthy volunteers welcome
- Sponsor
- PATH
Malaria,Falciparum
Safety and Immunogenicity of SUM-101 Malaria Vaccine in Children and Infants Living in Burkina Faso
This clinical trial aims to learn about the safety and immunogenicity of the blood-stage malaria vaccine candidate SUM-101 in infants and children, paving the way for its incorporation into a multi-stage malaria vaccine.
- Trial name
- SUM-101 (NCT06618885)
- Testing
- SUM-101
- Where
- Burkina Faso
- Volunteers
- 39 people, healthy volunteers welcome
- Sponsor
- European Vaccine Initiative
Malaria (Plasmodium Falciparum)
Dose Finding Trial of R21/Matrix-M in School Children
This trial is a double-blind, randomised, trial recruiting participants from the R21 phase IIb trial (VAC 076) which took place between May 2019 and July 2023 in Nanoro, Burkina Faso.
- Trial name
- NCT07074665
- Testing
- 5µg R21/50µg Matrix-M, 10µg R21/50µg Matrix-M
- Where
- Burkina Faso
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- University of Oxford
Malaria in Pregnancy, Pregnancy Related
MiMBa Pregnancy Registry
The MiMBa (Malaria in Mothers and Babies) Pregnancy Registry aims to generate robust evidence on the safety of a range of antimalarials when used in pregnancy, particularly in the first trimester.
- Conditions
- Malaria in Pregnancy, Pregnancy Related, Congenital Anomaly
- Trial name
- NCT04825782
- Where
- 2 sites in Burkina Faso, Kenya
- Volunteers
- 15,391 people, healthy volunteers welcome
- Sponsor
- Liverpool School of Tropical Medicine
Anemia, Iron Deficiency
Co-administration of Calcium and Multiple Micronutrient Supplements for Maternal and Newborn Hemoglobin and Iron Status
The World Health Organization (WHO) currently recommends the pregnant women receive iron-containing supplements and, in settings where calcium intake is low, calcium supplements.
- Trial name
- CaMMS (NCT06568315)
- Testing
- Concurrent multiple micronutrient and calcium supplementation, Separate multiple micronutrient and calcium supplementation
- Where
- 2 sites in Burkina Faso, Pakistan
- Volunteers
- 3,200 people, healthy volunteers welcome
- Sponsor
- Johns Hopkins Bloomberg School of Public Health
Malaria (Plasmodium Falciparum)
Challenge Trial of PfSPZ-LARC2 Vaccine in Burkina Faso
This is a randomized, double-blind, placebo-controlled, Phase 1 trial of Plasmodium falciparum (Pf) late liver stage-arresting replication-competent (LARC) sporozoite (SPZ) malaria vaccine (Sanaria® PfSPZ-LARC2 Vaccine)…
- Trial name
- BFSPZL3 (NCT07730177)
- Testing
- PfSPZ-LARC2 Vaccine, PfSPZ Challenge, Normal Saline
- Where
- Burkina Faso
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- Sanaria Inc.
Severe Acute Malnutrition
Mother Screening for Relapse Using Mid-upper Arm Circumference Among Children Recovered From Severe Acute Malnutrition
The investigators propose a pilot randomized controlled trial to train mothers to screen their children post-discharge for relapse based on MUAC criteria to facilitate timely identification and referral to care for children who…
- Trial name
- NCT05932992
- Testing
- Mother education on how to perform MUAC assessment
- Where
- Burkina Faso
- Volunteers
- 400 people, healthy volunteers welcome
- Sponsor
- University of California, San Francisco
Health Education, Health Communication
Evaluation of "C'Est La Vie!" Digital Health Education
The University of California, Los Angeles (UCLA) will lead the online evaluation of four digital health campaigns developed by a non-governmental organization (NGO), Réseau Africain de l'Éducation pour la Santé (RAES), or African…
- Trial name
- NCT07636629
- Testing
- Evaluating how to deliver messages to young people online
- Where
- 3 sites in Burkina Faso, Côte d’Ivoire and 1 more
- Volunteers
- 492 people, healthy volunteers welcome
- Sponsor
- University of California, Los Angeles
Typhoid
Immunogenicity and Tolerability of Booster Typhoid Conjugate Vaccine (TCV) 5-6 Years After Initial Dose in Children in Burkina Faso
This study evaluated the persistence of immunity following primary typhoid conjugate vaccination in early childhood and assessed the immunogenicity and safety of a booster dose administered 5-6 years later.
- Trial name
- NCT07624175
- Testing
- Vi capsular polysaccharide-CRM197 conjugate vaccine (Vi-CRM), 0.5 mL IM
- Where
- Burkina Faso
- Volunteers
- 147 people, healthy volunteers welcome
- Sponsor
- Kathleen Neuzil
Malaria (Plasmodium Falciparum)
Field Trial of PfSPZ-LARC2 Vaccine in Burkinabe Adults
This is a phase 2 clinical trial of a Plasmodium falciparum (Pf) late liver stage-arresting replication-competent (LARC) sporozoite (SPZ) vaccine (Sanaria® PfSPZ-LARC2 Vaccine) that will assess field efficacy in Africa.
- Trial name
- BFSPZL2 (NCT07385287)
- Testing
- Genetically attenuated PfSPZ Vaccine, Normal Saline (0.9% Sodium Chloride)
- Where
- Burkina Faso
- Volunteers
- 180 people, healthy volunteers welcome
- Sponsor
- Sanaria Inc.
Schistosomiasis
A Study to Evaluate the Safety, Tolerability, and Immunogenicity of the rSm-p80 + GLA-SE (SchistoShield®) Candidate Vaccine in Healthy Adults in Burkina Faso and Madagascar
The goal of this phase 1b, multicenter, randomized, placebo-controlled, observer-blinded, dose-escalation study is to assess the safety, tolerability, and immunogenicity of a three-dose regimen, spaced four weeks apart, given…
- Trial name
- NCT05762393
- Testing
- rSm-p80 + GLA-SE
- Where
- 2 sites in Burkina Faso, Madagascar
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- International Vaccine Institute
HIV/AIDS
Access to PrEP for MSM: Acceptability and Feasibility in Community-based Clinics in West Africa (CohMSM-PrEP)
This demonstration project will assess the acceptability and feasibility of pre-exposure prophylaxis (PrEP) for men who have sex with men (MSM) as part of a comprehensive HIV prevention package in community-based clinics in West…
- Trial name
- CohMSM-PrEP (NCT03459157)
- Testing
- HIV prevention package including PrEP
- Where
- 4 sites in Burkina Faso, Côte d’Ivoire and 2 more
- Volunteers
- 649 people, healthy volunteers welcome
- Sponsor
- ANRS, Emerging Infectious Diseases
Malaria Falciparum, Malaria Infection
Age De-escalation Safety Trial of PfSPZ-LARC2 Vaccine in Burkina Faso
This is a first-in-humans randomized, double-blind, placebo-controlled, age de-escalation Phase 1 trial of Plasmodium falciparum (Pf) late liver stage-arresting replication-competent (LARC) sporozoite (SPZ) malaria vaccine…
- Trial name
- NCT06652737
- Testing
- PfSPZ-LARC2 Vaccine
- Where
- Burkina Faso
- Volunteers
- 75 people, healthy volunteers welcome
- Sponsor
- Sanaria Inc.
HIV Infection
Feasibility and Interest of a HIV Quarterly Preventive Global Care in Men Who Have Sex With Men in Sub-Saharan Africa
The objective of the study is to evaluate the feasibility and interest of a HIV quarterly preventive global care for men who have sex with men (MSM) in sub-Saharan Africa to help reducing HIV incidence in this key population…
- Trial name
- CohMSM (NCT02626286)
- Testing
- HIV quarterly global care
- Where
- 4 sites in Burkina Faso, Côte d’Ivoire and 2 more
- Volunteers
- 885 people, healthy volunteers welcome
- Sponsor
- ANRS, Emerging Infectious Diseases
Severe Malaria, Uncomplicated Malaria
Host Immune and Metabolic Determinants of Sexual Conversion in Plasmodium Parasites IMMETASEX
Understanding the sexual conversion of the malaria parasite is essential to interrupt malaria transmission. A new tool is developed that, based on expression analysis of sexual stage biomarkers, will estimate sexual conversion…
- Conditions
- Severe Malaria, Uncomplicated Malaria, Asyptomatic Plasmodium Infection
- Trial name
- IMMETASEX (NCT06064591)
- Where
- 3 sites in Belgium, Burkina Faso and 1 more
- Volunteers
- 458 people, healthy volunteers welcome
- Sponsor
- Institute of Tropical Medicine, Belgium